TheGc2Allele of the Vitamin D Binding Protein Is Associated with a Decreased Postmenopausal Breast Cancer Risk, Independent of the Vitamin D Status
- 1 June 2008
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 17 (6), 1339-1343
- https://doi.org/10.1158/1055-9965.epi-08-0162
Abstract
Vitamin D pathway gene polymorphisms may influence breast cancer risk by altering potential anticarcinogenic effects of vitamin D. The association between polymorphisms in the vitamin D binding protein (Gc) and postmenopausal breast cancer risk, with additional focus on the influence of serum 25-hydroxyvitamin D [25(OH)D], the biomarker for vitamin D status in humans, has not been examined thus far. We assessed the combined effects of two known functional polymorphisms in the Gc gene (rs4588 and rs7041), composing the phenotypic alleles Gc1s, Gc1f (combined: Gc1), and Gc2, on postmenopausal breast cancer risk and potential effect modification by 25(OH)D status in a population-based case-control study including 1,402 cases and 2,608 matched controls. Odds ratios (OR) for breast cancer risk adjusted for potential confounders were calculated for Gc genotypes. ANOVA was used to compare geometric means of serum 25(OH)D across Gc genotypes. Serum 25(OH)D concentrations in the control group significantly differed by Gc genotype, being lowest in Gc2 allele carriers. The geometric means of 25(OH)D were 53.0, 47.8, and 40.4 nmol/L for Gc1-1, Gc2-1, and Gc2-2 genotypes, respectively (Ptrend < 0.0001). Gc2-2 genotype was associated with a significantly decreased risk of postmenopausal breast cancer with an odds ratio (95% confidence interval) of 0.72 (0.54-0.96), compared with homozygote Gc1s allele carriers. No interaction between 25(OH)D status and Gc genotype was observed, nor did the association change considerably after adjustment for 25(OH)D status. Our results provide evidence for a serum 25(OH)D-independent effect of Gc2 allele carrier status in postmenopausal breast cancer. (Cancer Epidemiol Biomarkers Prev 2008;17(6):1339–43)Keywords
This publication has 18 references indexed in Scilit:
- Retracted: Immunotherapy of metastatic breast cancer patients with vitamin D‐binding protein‐derived macrophage activating factor (GcMAF)International Journal of Cancer, 2007
- Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control studyCarcinogenesis: Integrative Cancer Research, 2007
- Vitamin D and prevention of breast cancerActa Pharmacologica Sinica, 2007
- Vitamin D and cancerThe Journal of Steroid Biochemistry and Molecular Biology, 2006
- Associations Between Polymorphisms in the Vitamin D Receptor and Breast Cancer RiskCancer Epidemiology, Biomarkers & Prevention, 2005
- Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D and Risk of Breast CancerCancer Epidemiology, Biomarkers & Prevention, 2005
- Female Premenopausal Fracture Risk Is Associated With Gc PhenotypeJournal of Bone and Mineral Research, 2004
- New insights into the mechanisms of vitamin D actionJournal of Cellular Biochemistry, 2003
- Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer.Endocrine-Related Cancer, 2002
- The Effects of Chemotherapy Including Cisplatin on Vitamin D Metabolism.Endocrine Journal, 1993